These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6816315)

  • 1. Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial.
    Wada T; Koyama H; Terasawa T
    Breast Cancer Res Treat; 1981; 1(1):53-8. PubMed ID: 6816315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
    Kitamura M; Tominaga T; Hayashi K; Takahashi I; Kosaki G
    Gan To Kagaku Ryoho; 1985 Jan; 12(1):111-7. PubMed ID: 3917652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer.
    Hata Y; Takahashi H; Todo S; Okazaki M; Asaishi K; Hirata K; Okushiba S; Kato H; Uchino J
    Breast Cancer; 2003; 10(2):134-9. PubMed ID: 12736566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.
    Mouridsen HT; Palshof T; Rose C
    Recent Results Cancer Res; 1980; 71():169-77. PubMed ID: 6988913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
    Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
    J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of chemo-endocrine therapy in advanced breast cancer--a combined administration of tamoxifen, tegafur, and cyclophosphamide].
    Wada T; Koyama H; Nishizawa Y; Iwanaga T; Terasawa T
    Nihon Gan Chiryo Gakkai Shi; 1982 Dec; 17(8):2093-100. PubMed ID: 6820378
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
    Sakai K; Kosaki G; Seno T; Taguchi T; Terasawa T; Nakao K; Koyama H; Oshima A
    Cancer Chemother Pharmacol; 1996; 37(6):587-92. PubMed ID: 8612314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemo-endocrine therapy for advanced breast cancer--a combined treatment with tamoxifen and FT 207-- (author's transl)].
    Wada T; Koyama H; Nishizawa Y; Takahashi Y; Fukuda I; Iwanaga T; Terasawa T
    Nihon Gan Chiryo Gakkai Shi; 1981 Feb; 16(1):51-5. PubMed ID: 6790640
    [No Abstract]   [Full Text] [Related]  

  • 9. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
    Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
    Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
    Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
    Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
    Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
    J Clin Oncol; 1986 Feb; 4(2):186-93. PubMed ID: 2868074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Long HJ; Gerstner JG; Windschitl HE
    J Clin Oncol; 1988 May; 6(5):825-31. PubMed ID: 3284975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
    Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
    Breast Cancer Res Treat; 1981; 1(1):59-68. PubMed ID: 6756508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.